Announcement
GENERAL: PEB: International Urology Experts Present on Cxbladder
11:02am
PEB
20/05/2019 11:02
GENERAL
NOT PRICE SENSITIVE
REL: 1102 HRS Pacific Edge Limited
GENERAL: PEB: International Urology Experts Present on Cxbladder
International Urology Experts Present on Cxbladder
Pacific Edge Limited (NZX: PEB) is hosting an event today in Auckland, with
two internationally renowned urologists presenting on the performance and
commercial use of Cxbladder in their USA and New Zealand clinical settings
respectively. Videos of their presentations can be viewed on Pacific Edge's
website at:
https://www.cxbladder.com/nz/clinician-information/resources/
Dr Sia Daneshmand: Associate Professor of Urology and Director of Urologic
Oncology, Keck Medical Centre - University of Southern California. Dr
Daneshmand recently presented at the prestigious South East Asian Urofair
2019 conference in Singapore, on Urine Biomarkers and the Detection of
Urothelial Carcinoma.
Dr Madhusudan Koya: Clinical Director of Urology at Waitemata DHB and
President of the New Zealand section of the Urological Society of Australia
and New Zealand. Dr Koya also presented at Urofair 2019 and will be
discussing the real world use of Cxbladder and its clinical utility in New
Zealand.
Dr Daneshmand's and Dr Koya's presentations demonstrate the accumulated
clinical evidence underpinning the adoption of Cxbladder, its commercial use
and the benefits for patients, physicians, healthcare funders and providers
alike.
ENDS
For more information contact:
David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800
OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer
diagnostic company specialising in the discovery and commercialisation of
diagnostic and prognostic tests for better detection and management of
cancer. Its non-invasive, simple to use and accurate Cxbladder tests enable
the detection of bladder and other urinary tract cancers from a small volume
of a patients' urine. Cxbladder provides actionable results and better
detection and management of urothelial cancer. The company is developing and
commercialising its range of Cxbladder tests globally and has two wholly
owned accredited laboratories in New Zealand and the USA. The company's
products have been tested and validated in multiple international clinical
studies.
ABOUT Cxbladder Triage
Cxbladder Triage accurately identifies patients with haematuria who have a
low probability of bladder cancer and may not require a more extensive
urological evaluation. Cxbladder Triage is a tool for use by clinicians and
physicians in primary evaluation of patients with haematuria and is intended
to reduce the need for an expensive and invasive work-up in patients who have
a low probability of having urothelial cancer.
ABOUT Cxbladder Detect
Cxbladder Detect provides clinicians with a quick, cost effective and
accurate measure of the presence of the cancer as an effective adjunct to
cystoscopy. Is often used in conjunction with Cxbladder Triage to provide
greater rule-out and resolution of patients who have UC.
ABOUT Cxbladder Monitor
Cxbladder Monitor allows urologists to monitor bladder cancer patients for
recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and
requires life-long surveillance. Cxbladder Monitor accurately identifies
patients with a prior history of urothelial cancer whose Cxbladder Monitor
score shows that they have a low probability of recurrent urothelial cancer.
Cxbladder Monitor is designed to be used as the preferred adjunct test to
cystoscopy in the management of patients for ongoing evaluation of recurrent
bladder cancer.
ABOUT Cxbladder Resolve
Cxbladder Resolve identifies those patients who are likely to have aggressive
or more advanced bladder cancer. Cxbladder Resolve, when used as part of the
primary evaluation of haematuria and/or in conjunction with other Cxbladder
tests (Triage, Detect), is designed to assist clinicians by accurately
identifying patients with a high probability of having high grade or late
stage bladder cancer, for whom alternative or expedited treatment options may
be warranted, or who can be prioritised for further investigation in high
throughput settings.
Refer to www.cxbladder.com for more information.
End CA:00334769 For:PEB Type:GENERAL Time:2019-05-20 11:02:21
Click here
to view related attachments.
